Anuh Pharma (ANUHPHR)
Slow GrowerFairStock Score: 44/100 — MIXED
Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹76.21 |
| Market Cap | ₹763.81 Cr |
| P/E Ratio | 18.59 |
| ROCE | 17.24% |
| ROE | 13.8% |
| Dividend Yield | 1.97% |
| Profit Growth | 37.3% |
| Debt/Equity | 0 |
| Sales Growth | 3.9% |
| Promoter Holding | 71.82% |
| 52-Week Range | ₹67 — ₹99.5 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹35.14 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At first glance, Anuh Pharma looks like a reasonably run pharmaceutical business, not a thrilling one. The numbers I respect most are the absence of leverage and the consistent profitability. With debt-to-equity of 0.00 and ROCE of 17.24%, the company is generating decent returns without relying on borrowed money. ROE of 13.80% is acceptable, though not extraordinary. Growth is genuinely impressive: sales up 23.62% and profits up 30.08%. A PEG ratio of 0.69 suggests the market is paying less than the growth rate; if that growth persists, the valuation is not demanding. At ₹81.70, the stock trades at 18.49 times earnings and 2.72 times book value. That is not cheap in an absolute Graham sense, but for a zero-debt company with a 71.82% promoter holding, I can accept some premium. The Piotroski F-Score of 7/9 supports a healthy financial picture. The 1.94% dividend is a small reward while waiting. But I must be cautious. The FairStock score of 49/100 reminds me this is a mixed picture. A 52-week range of ₹67 to ₹94.89 tells me the market itself is uncertain. The latest quarter—₹197 crore sales and ₹13 crore net profit—is fine, but one quarter proves nothing. I do not see a wide, impenetrable moat from these figures. This may be a fast grower priced reasonably, but I would want several more years of evidence before calling it a stalwart. In Buffett's temple, great businesses combine high returns on capital with durable advantages. Anuh has good returns and no debt, but I need to see whether the growth is built on a lasting edge or on industry tailwinds. For an Indian retail investor, it deserves a watchlist, not blind worship.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer